How many 8-K filings has Processa Pharmaceuticals, Inc. filed?

Processa Pharmaceuticals, Inc. (PCSA) has 33 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Processa Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Processa Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Processa Pharmaceuticals, Inc. (PCSA) — 8-K Filings

All 8-K filings from Processa Pharmaceuticals, Inc.. Browse 33 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (33)

Processa Pharmaceuticals Files 8-K on Security Holder Rights — Dec 15, 2025 Risk: medium
Processa Pharmaceuticals, Inc. filed an 8-K on December 15, 2025, reporting events as of December 12, 2025. The filing indicates material modifications to the r
Processa Pharmaceuticals Files 8-K — Sep 12, 2025 Risk: low
On September 11, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a submission of matters to a vote of security holders and includ
Processa Pharmaceuticals Files 8-K on Security Holder Votes — Sep 10, 2025 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain
Processa Pharmaceuticals Files 8-K on Security Holder Vote — Sep 2, 2025 Risk: low
On September 2, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security
Processa Pharmaceuticals Files 8-K — Aug 25, 2025 Risk: low
On August 25, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no sp
Processa Pharma Faces Delisting Concerns — Aug 8, 2025 Risk: high
Processa Pharmaceuticals, Inc. filed an 8-K on August 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indica
Processa Pharmaceuticals Files 8-K — Aug 7, 2025 Risk: medium
On August 4, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securi
Processa Pharmaceuticals Files 8-K — Jul 25, 2025 Risk: low
On July 25, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indi
Processa Pharmaceuticals Files 8-K — Jul 18, 2025 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on July 18, 2025, reporting on the submission of matters to a vote of security holders and financial statements/exhi
Processa Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jul 15, 2025 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on July 15, 2025, reporting on matters submitted to a vote of its security holders. The filing does not contain spec
Processa Pharmaceuticals Enters Material Definitive Agreement — Jul 1, 2025 Risk: medium
On June 27, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company, formerly known as Heatwurx, Inc., is incorporated in
Processa Pharmaceuticals Files 8-K: Material Agreement & Shareholder Vote — Jun 30, 2025 Risk: medium
On June 24, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company also submitted matters to a vote of its security hold
Processa Pharmaceuticals Enters Material Definitive Agreement — Jun 18, 2025 Risk: medium
On June 17, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company, formerly known as Heatwurx, Inc. until October 28, 2
8-K Filing — Jun 17, 2025
Processa Pharmaceuticals Files Current Report — Feb 11, 2025 Risk: low
Processa Pharmaceuticals, Inc. reported on February 11, 2025, that its common stock trades under the ticker PCSA on the Nasdaq Capital Market. The company is in
Processa Pharmaceuticals Faces Delisting Concerns — Feb 10, 2025 Risk: high
Processa Pharmaceuticals, Inc. filed an 8-K on February 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. Th
Processa Pharmaceuticals Files 8-K — Jan 30, 2025 Risk: medium
On January 27, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company also provided a Regulation FD disclosure and filed
Processa Pharmaceuticals Changes Independent Auditor — Nov 6, 2024 Risk: medium
Processa Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, reporting a change in its certifying accountant as of October 31, 2024. The company previously
Processa Pharmaceuticals Files 8-K — Oct 2, 2024 Risk: low
On October 2, 2024, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine up
Processa Pharmaceuticals Files 8-K — Aug 28, 2024 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on August 28, 2024, reporting other events and financial statements. The company, formerly known as Heatwurx, Inc.,
Processa Pharmaceuticals Appoints New Chief Medical Officer — Jul 30, 2024 Risk: medium
On July 30, 2024, Processa Pharmaceuticals, Inc. filed an 8-K report detailing the appointment of Dr. Michael H. Smith as Chief Medical Officer. Dr. Smith bring
Processa Pharmaceuticals Elects New Director — Jul 17, 2024 Risk: low
On July 16, 2024, Processa Pharmaceuticals, Inc. announced a change in its board of directors, with the election of Dr. David J. Gury to the board. The company
Processa Pharmaceuticals Files 8-K on Shareholder Votes & Financials — Jul 2, 2024 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on July 2, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 28
Processa Pharmaceuticals Enters Material Definitive Agreement — May 21, 2024 Risk: medium
On May 21, 2024, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company, previously known as Heatwurx, Inc., is incorporated i
Processa Pharmaceuticals Files 8-K — Apr 11, 2024 Risk: low
On April 11, 2024, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhib
Processa Pharmaceuticals Files 8-K with Corporate Updates — Apr 4, 2024 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on April 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits as of April 3, 2024. Th
Processa Pharmaceuticals Files 8-K on Feb 20 Event — Feb 21, 2024 Risk: low
Processa Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing is a current report under Se
Processa Pharma Files 8-K, Confirms Nasdaq Listing & Corporate Details — Feb 6, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on February 6, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. The filing confirms the com
Processa Pharma Reports Material Definitive Agreement; Details Undisclosed — Jan 30, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on January 30, 2024, reporting an "Entry into a Material Definitive Agreement" on January 26, 2024. While the filing
Processa Pharma Files 8-K on Other Events, Financials — Jan 25, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, to report "Other Events" and "Financial Statements and Exhibits." This filing primarily serves
Processa Pharma Files 8-K, Confirms Nasdaq Listing — Jan 19, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on January 19, 2024, primarily to disclose general corporate information and confirm its registration on the Nasdaq
Processa Pharma 8-K: Material Modifications to Security Holder Rights — Jan 18, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, to report material modifications to the rights of its security holders and amendments to its Ar
Processa Pharma Files 8-K, Confirms Nasdaq Listing — Jan 8, 2024
Processa Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX